SCHEMBL30681884

SCHEMBL30681884

Cc1ncc(OB(O)O)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29092844 0.90 — —
SCHEMBL16908557 0.77 FTO (0.40) —
SCHEMBL27615271 0.77 HSD17B10 (0.45) —
SCHEMBL16610671 0.76 HDAC1 (0.39) —
SCHEMBL31024119 0.76 — —
Hydrochloric Acid SCHEMBL3867119 0.76 KDM4E (0.44) —
SCHEMBL30693631 0.76 MEN1 (0.33) —
SCHEMBL5424020 0.76 KMT2A (0.42) —
SCHEMBL31261122 0.74 ALDH1A1 (0.30) —
SCHEMBL28451946 0.73 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119822791-A Extrusion-molded magnesium oxide tube and processing technology thereof 盐城市林宇电器有限公司 2025-04-15 — — CN claimed
CN-117203212-A Process for producing (2-methylpyrimidin-5-yl) boric acid derivative 株式会社钟化 2023-12-08 — — CN claimed
CN-119822791-A Extrusion-molded magnesium oxide tube and processing technology thereof 盐城市林宇电器有限公司 2025-04-15 — — CN disclosed
WO-2024240213-A1 FUSED TRICYCLIC SUBSTITUTED ISOXAZOLIDINYL UREA DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海海雁医药科技有限公司 2024-11-28 — — WO disclosed
CN-117203212-A Process for producing (2-methylpyrimidin-5-yl) boric acid derivative 株式会社钟化 2023-12-08 — — CN disclosed
CN-117203212-A Process for producing (2-methylpyrimidin-5-yl) boric acid derivative 株式会社钟化 2023-12-08 — — CN disclosed
CN-117203212-A Process for producing (2-methylpyrimidin-5-yl) boric acid derivative 株式会社钟化 2023-12-08 — — CN disclosed
Send feedback